More Capacity and Technology Translate to More Options

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

Emerging therapies are testing the capabilities of biologic drug manufacturing companies, as well as contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). Manufacturers are employing process optimization and scalable advanced technologies to produce more product in less floor space. In addition, CDMOs have stepped up investments in cell and gene therapy development and manufacturing While this consolidation means there are fewer competitors in the market, industry experts see benefits including standardization of methods, simplified vendor management, and use of advanced technologies.

Read this article in BioPharm International’s February 2020 Partnerships for Outsourcing eBook.

Article Details

BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Page: 6

Citation

When referring to this article, please cite it as R.Peters, “More Capacity and Technology Translate to More Options," BioPharm International Outsourcing ResourceseBook (February 2020).

Articles in this issue

over 5 years ago

Article

Lyophilization Services Gain Ground Amid Growing Biologics Market

over 5 years ago

Article

Biopharma Contract Market Update

over 5 years ago

Article

Building Strategic Relationships with CROs

over 5 years ago

Article

Digitalization: A CDMO’s Perspective

over 5 years ago

Article

Sourcing Success in Cell and Gene Therapy Development

over 5 years ago

Article

Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization

over 5 years ago

Article

Growth in Biologics Market Inspires Outsourcing

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!